- RecruitingPHASE1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
This study is looking at a new drug called CC-97540 for people with certain types of Multiple Sclerosis (MS) or a muscle weakness condition called Myasthenia Gravis (MG). We want to see if it's safe, how well people can handle it, and if it helps their condition.
For: Multiple Sclerosis · Myasthenia GravisUnited States · Belgium · France - RecruitingPHASE2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
This study is testing a new cell therapy called CC-97540 for people with lupus and lupus kidney disease. It aims to see if it's safe and effective when other treatments haven't worked well enough.
For: Lupus Erythematosus, Systemic · Lupus NephritisUnited States · Argentina · Austria - RecruitingPHASE1
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
This study is testing a new cell therapy called CC-97540 for severe autoimmune diseases like lupus and rheumatoid arthritis. It aims to see if it's safe, how well it works, and how the body handles it, especially when other treatments haven't helped.
For: Systemic Lupus Erythematosus · Idiopathic Inflammatory Myopathy · Systemic SclerosisUnited States · Belgium · France